Novartis (NYSE: NVS) announced plans to build a new facility in Morrisville, North Carolina, for manufacturing active pharmaceutical ingredients used in solid dosage tablets, capsules and RNA therapeutics.

The 56,200-square-foot facility represents the seventh new facility planned within a year of the company's announced $23 billion investment in US-based manufacturing, research and development. The addition will expand Novartis' presence in North Carolina to five facilities across three sites.

"Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US," said Vas Narasimhan, CEO of Novartis.

The company has been expanding its US manufacturing capacity since April 2025. Recent developments include breaking ground on a biomedical research center in San Diego, California in February 2026, and announcing a new manufacturing facility in Denton, Texas for radioligand therapies.

Novartis also announced a radioligand therapy manufacturing facility in Winter Park, Florida in January 2026, and broke ground on a manufacturing hub in North Carolina in December 2025 for solid dosage tablets, capsules and biologics production.

In November 2025, the company opened a radioligand therapy manufacturing facility in Carlsbad, California. The company is also expanding existing radioligand therapy facilities in Indianapolis, Indiana, and Millburn, New Jersey.

According to the press release, Novartis aims to establish end-to-end manufacturing for small and large molecules, radioligand therapies, RNA therapeutics, and cell and gene therapies in the US.